Related Experiment Video
Updated: May 4, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Acquired Factor VIII Inhibitor: A Rare Etiology for Bruisability and Anemia
Srikanth Seethala1, Keith Barnes1, Javier Corral1
1Department of Internal Medicine, Texas Tech University Health Sciences Center, 4800, Alberta Ave, El Paso, TX 79905 USA.
Abstract:
Acquired factor VIII inhibitor is a very rare cause of easy bruisability, muscular hematomas, and subsequent anemia in the elderly patient population. The incidence of acquired factor VIII inhibitor is one in one million. Here we report an elderly patient who presented to the hospital for bruising easily fatigue and was found to have acquired factor VIII inhibitor on further investigation. He responded to the treatment appropriately, and hemostasis was achieved successfully with recombinant VII concentrates and eradication of the inhibitor with Imuran and steroid combination.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Venous Thrombosis IV: Nursing Management

